Platinum chemotherapeutics are widely used to treat solid malignant tumors, including gastric cancer (GC). Drug resistance to platinum compounds may result in cancer relapse and decreased survival.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) belongs to the TNF superfamily, the expression of which has been demonstrated in a wide range of tissues. 1 TRAIL binds to five ...
Impact of Rituximab and/or High-Dose Therapy With Autotransplant at Time of Relapse in Patients With Follicular Lymphoma: A GELA Study Cancer is a leading cause of premature human death and commands ...
HGS-ETR1, the Company's antibody to TRAIL receptor 1, is the most advanced of any product in development that targets the TRAIL apoptosis pathway. About Human Genome Sciences The mission of HGS is to ...
Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of cancer. HGS1029, a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins, is expected to ...
Not surprisingly, many major pharmaceutical companies recognize the value of apoptosis research. Understanding and controlling programmed cell death is expected to yield new drug discoveries and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback